https://www.selleckchem.com/products/ha130.html
Results A total of 47 randomized controlled trials (13,826 patients), covering 23 unique treatment regimens, were included a total of 29 reported HBsAg loss, 36 reported HBeAg seroconversion and 37 reported HBV DNA suppression. For both HBsAg loss and HBeAg seroconversion, pegylated interferon-based regimens were the most effective strategy in both HBeAg-positive and HBeAg-negative patients. On the other hand, for HBV DNA suppression, nucleosides-based regimens were the most effective strategy in both HBeAg-positive and HBeAg-negative pat
Aimer
Commentaire
Partagez
